Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact
Authors' conclusion
The risk for ATE varies according to sex, age, and cancer progression and type. Antithrombotic therapy after ATE is associated with improved survival among patients with cancer.
Study context
- Population
- Patients with cancer, Osaka Cancer Registry linked with administrative data, 2010–201542.3% women, median age 70
- Participants
- 97,448 patients
- Exposure
- Antithrombotic therapy vs none after arterial thromboembolism (ATE)
- Outcome
- Incidence of ATE, with death as a competing risk
- Follow-up
- 5 years after cancer diagnosis
Methodological detailsmulticentre, registry-linked administrative data
- Multicentre
- Registry-linked administrative data
Main finding
As reported in the abstract
Cumulative incidence of ATE
- 1-year cumulative incidence
- 1.29%
- 2-year cumulative incidence
- 1.77%
- 3-year cumulative incidence
- 2.05%
- 4-year cumulative incidence
- 2.22%
- 5-year cumulative incidence
- 2.32%
Observational data: associations, not effects.
Further findings
| Outcome | RMST difference (days) (95% CI) | P value | |
|---|---|---|---|
| RMST after ATEAntithrombotic therapyvs No antithrombotic therapy90-day | 13.3 (10.4–16.2) | P < 0.001 | |
| RMST after ATEAntithrombotic therapyvs No antithrombotic therapy1-year | 57.8 (43.1–72.5) | P < 0.001 | |
| −50050100Difference, days (linear scale) |
Predictors of ATE
- Male sex, advanced age, advanced cancer stage and hematologic malignancies correlated with high ATE risk
Mortality, ATE vs no ATE
- 2-fold increased risk for mortality with ATE
Restricted mean survival time (RMST) after ATE
- RMST differences varied by cancer stage
Original publication
Arterial Thromboembolism in Japanese Patients With Cancer: Incidence, Predictors, and Survival Impact. JACC CardioOncol. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →